

## **Biographical Sketch**

Declan Quinn, Mb, FRCPC  
Professor and Head  
Division of Child and Adolescent  
Psychiatry  
Department of Psychiatry,  
College of Medicine,  
University of Saskatchewan  
Canada

Declan Quinn is a Child and Adolescent at the University of Saskatchewan in Canada. He was a founding member of CADDRA (Canadian ADHD Resource Alliance) in 2005 and currently President of CADDRA, which has developed the Canadian ADHD Practice Guidelines and currently in the 3<sup>rd</sup> edition.

He has been involved in research in ADHD since the late 1980's and has a particular focus on pharmacokinetic and pharmacodynamics. He has completed studies on the isomers of Methylphenidate that led to the introduction of d-Methylphenidate as a treatment for ADHD. He has been involved in key studies looking at the Pharmacokinetics including Bioavailability of different once a day preparations of d-Amphetamine and Methylphenidate in ADHD.

Dr Quinn has been in the past 3 years a consultant to / member of advisory board of / and/or speaker with worked with Janssen, Shire, Perdue, Novartis and Ironshore Pharmaceuticals. He is not an employee of these companies